David Greeley, MD/FAAN, AriBio Co., Ltd and Northwest Neurological in Spokane, WA, has been involved in research focusing on anti-amyloid monoclonal antibodies as potential therapeutic agents for Alzheimer’s disease (AD). These antibodies have shown tremendous efficacy in removing amyloid plaques, which are a hallmark of AD pathology. Dr Greeley believes that anti-amyloid monoclonal antibody drugs hold promise, but are not the whole solution. To heighten the potential clinical benefits, Dr Greeley suggests that combination strategies are the key next step. For example, Dr Greeley and his team are currently investigating AR1001, an oral, brain-penetrant PD5 inhibitor, in patients with Alzheimer’s disease and hope to conduct a clinical study in which patients are treated with this agent, as well as an anti-amyloid agent. This interview took place at the AD/PD™ 2023 congress in Gothenburg, Sweden.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
